Interstitial lung disease associated to erlotinib treatment: a case report.
BACKGROUND
Few cases of pulmonary toxicity related to epidermal growth factor receptor-targeted agents have been described.


METHODS
We report a case of a 63-year-old white male with stage IV non-small cell lung cancer treated with erlotinib who developed a interstitial lung disease.


CONCLUSIONS
Respiratory symptoms during treatment with erlotinib should alert clinicians to rule out pulmonary toxicity. Early erlotinib withdrawal and corticoid administration were successful.
Unidad de Cuidados Intensivos, Hospital de Sant Pau i Santa Tecla, Rambla Vella, 14, 43003, Tarragona, Spain. castilloduran@hotmail.com.
Yolanda
Y
Del Castillo
Paulina
P
Espinosa
Fernanda
F
Bodí
Raquel
R
Alcega
Emma
E
Muñoz
Carlos
C
Rabassó
David
D
Castander